Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T Cells in Recurrent or Refractory CD19+ B-ALL
NCT03599375Phase 1Unknown
- Start
- May 2019
- Primary completion
- Dec 2020
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
01
Overview
Phase 1, open-label, single-arm trial of CD19-targeted CAR T cells in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoint: Overall Response Rate at 3 months. Status: unknown.
02
Drugs
CD19-targeted CAR T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03599375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599375.